Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs

← catalyst calendar

NCT06175637 · readout in 284 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

—

Status

Active, not recruiting

Study type

Observational

Enrollment

409actual

Sites

Country

China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-12-20

actual

When the study began enrolling

Primary completion

2027-05-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-05-30

estimated

The whole study's end, after follow-up

First posted

2023-12-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Neurofibroma, Plexiform

Primary outcomes

what the primary-completion date above is the date OF

NF1-PN patient demographics and disease characteristics at baseline and during selumetinib treatment